As global markets navigate a period of economic uncertainty, the Hong Kong market has shown resilience, with the Hang Seng Index experiencing modest fluctuations. Against this backdrop, growth stocks with high insider ownership can be particularly compelling due to their potential for robust performance and strong alignment between management and shareholder interests. In this article, we will explore three SEHK-listed growth companies that insiders are backing, highlighting their potential in the current market environment.
Top 10 Growth Companies With High Insider Ownership In Hong Kong
| Name | Insider Ownership | Earnings Growth |
| Laopu Gold (SEHK:6181) | 36.4% | 34.7% |
| Akeso (SEHK:9926) | 20.5% | 54.7% |
| Fenbi (SEHK:2469) | 33.1% | 22.4% |
| Zylox-Tonbridge Medical Technology (SEHK:2190) | 18.8% | 69.8% |
| Pacific Textiles Holdings (SEHK:1382) | 11.2% | 37.7% |
| Zhejiang Leapmotor Technology (SEHK:9863) | 14.7% | 78.9% |
| DPC Dash (SEHK:1405) | 38.2% | 104.2% |
| Beijing Airdoc Technology (SEHK:2251) | 29.1% | 93.4% |
| Kindstar Globalgene Technology (SEHK:9960) | 16.5% | 88% |
| Biocytogen Pharmaceuticals (Beijing) (SEHK:2315) | 13.9% | 109.2% |
Below we spotlight a couple of our favorites from our exclusive screener.
Meituan (SEHK:3690)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Meituan is a technology retail company operating in the People's Republic of China with a market cap of approximately HK$777.88 billion.
Operations: The company's revenue segments include New Initiatives generating CN¥77.56 billion and Core Local Commerce contributing CN¥228.13 billion.
Insider Ownership: 11.6%
Meituan, a prominent growth company with high insider ownership in Hong Kong, has demonstrated significant financial performance. The company reported half-year sales of CNY 155.53 billion and net income of CNY 16.72 billion, reflecting substantial year-over-year growth. Earnings per share doubled from the previous year. Meituan's recent buyback program repurchased over 221 million shares for HKD 14.35 billion, indicating strong confidence in its future prospects despite no substantial insider buying recently.
- Dive into the specifics of Meituan here with our thorough growth forecast report.
- In light of our recent valuation report, it seems possible that Meituan is trading beyond its estimated value.
Techtronic Industries (SEHK:669)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Techtronic Industries Company Limited designs, manufactures, and markets power tools, outdoor power equipment, and floorcare and cleaning products across North America, Europe, and internationally with a market cap of HK$199.19 billion.
Operations: The company's revenue segments include Power Equipment, generating $13.23 billion, and Floorcare & Cleaning, contributing $965.09 million.
Insider Ownership: 25.4%
Techtronic Industries, with significant insider ownership, reported half-year sales of US$7.31 billion and a net income of US$550.37 million, reflecting solid year-over-year growth. The company announced an interim dividend of HKD 1.08 per share and appointed Steven Philip Richman as an Executive Director. Forecasts indicate revenue growth faster than the Hong Kong market at 8.5% annually, with earnings expected to grow at 15.3% per year, underscoring its robust growth potential despite slower-than-expected substantial insider buying recently.
- Click to explore a detailed breakdown of our findings in Techtronic Industries' earnings growth report.
- Our valuation report here indicates Techtronic Industries may be overvalued.
Akeso (SEHK:9926)
Simply Wall St Growth Rating: ★★★★★★
Overview: Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs with a market cap of HK$62.51 billion.
Operations: The company generates CN¥1.87 billion from the research, development, production, and sale of biopharmaceutical products.
Insider Ownership: 20.5%
Akeso, a growth company with high insider ownership, is forecasted to grow earnings by 54.67% annually and become profitable within three years. Despite trading at 45.6% below its estimated fair value and experiencing shareholder dilution over the past year, Akeso's revenue is projected to outpace the Hong Kong market significantly at 33.1% per year. Recent clinical trial results for ivonescimab show promising efficacy in treating various cancers, supporting its long-term growth potential despite recent volatility in share price.
- Delve into the full analysis future growth report here for a deeper understanding of Akeso.
- Upon reviewing our latest valuation report, Akeso's share price might be too optimistic.
Taking Advantage
- Access the full spectrum of 46 Fast Growing SEHK Companies With High Insider Ownership by clicking on this link.
- Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
- Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.
Curious About Other Options?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About SEHK:9926
Akeso
A biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs.
Exceptional growth potential with adequate balance sheet.
